• Cassava Sciences, Inc. has been invited to present at the H.C.
• Wainwright 26th Annual Global Investment Conference in New York.
• The company is a clinical-stage biotechnology company focused on Alzheimer’s disease.
• Rick Barry, Cassava’s Executive Chairman, will join in a ‘fireside chat’ with Vernon T.
• Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C.
AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present at the H.C. Wainwright 26th Annual Global Investment Conference, being held in New York.
Rick Barry, Cassava’s Executive Chairman, will join in a ‘fireside chat’ with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C. Wainwright.
Institutional investors who are registered for this conference may log into www.hcwevents.com to request a meeting with Cassava Sciences, pending availability.
Event details follow:
| Date: | Monday, September 9th |
| Time: | 3:00pm to 3:30 Eastern Time |
| Webcast: | https://journey.ct.events/view/d574c934-b104-45ac-bf42-07f169ce0d11 |
A live webcast will be available on the “Investors” page of Cassava Sciences’ website, www.CassavaSciences.com. An archived replay will be available for 90 days following the event.
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain.
For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450 or This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$27.95 |
| Daily Change: | -0.17 -0.60 |
| Daily Volume: | 844,891 |
| Market Cap: | US$1.340B |
September 09, 2024 July 17, 2024 May 10, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
